idea-022 · human · US
For application and removal only by a licensed clinician in an outpatient; wound-care, podiatry or foot-and-ankle clinic, to provide non-removable knee-high offloading; of the plantar foot between scheduled clinic visits in adults with diabetes and a; neuropathic plantar forefoot or midfoot ulcer, without active infection, osteomyelitis, or; critical limb ischemia, for whom a non-removable offloading device is clinically; appropriate.
Still being built — 5 of 8 wrap criteria met; nothing for you to decide yet. No department has been asked. 0 of 29 claims verified. Nobody has yet written down what it rests on.
A reusable, knee-high, rigid-shell offloading walker with a rocker sole and a plantar pressure-relief insole is closed on the patient's leg by a single-use closure set whose straps pass through a keyed lock that only a clinic tool opens. Each strap carries a frangible, visibly tamper-evident emergency release that the patient can break in an emergency, leaving an unmistakable sign that the device was opened. The clinic removes the closure at each scheduled visit (typically weekly) to inspect and debride the wound, then reapplies the walker with a fresh closure set. The functional target is the same as the published "instant total contact cast," a removable walker wrapped in cohesive bandage so it cannot easily be removed (claim 2unverified), with a lock replacing the bandage so the clinic can open and reclose it quickly and the patient can open it in an emergency. There are deliberately no electronics and no wear-time logging (see the FTO (freedom to operate) note in the design rationale).
In the mechanism, as the candidate file states it — the plain-language paragraph in ## Wrap has not been written yet. Domain: none linked
No business case yet, so nothing here says who writes the cheque. /business-case idea-022 builds one.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-022 replaces this list with the real one.
Why it scored what it did: Claims 12, 13, 14. Scored against the stated intended use (non-removable offloading, no healing claim). Both carried routes are believed Class I, and the one the Generator prefers (890.3475) is believed exempt, so review burden would be…the rest of this reasoning
close to nil. It is a 4 rather than a 5 because neither regulation, class, exemption nor product code has been read, and because it is not yet known whether exemption limits or FDA (US Food and Drug Administration)'s reading of a closed-on-limb assembly could push it off the Class I route. claim 14unverified prices the counterfactual: adding a healing claim means De Novo (De Novo classification request) with outcome data.
What would settle it: eCFR text of 21 CFR (Title 21 of the Code of Federal Regulations) 890.3475, 888.5940 and the 890.9/888.9 exemption limits, plus an FDA Product Classification database lookup for a product code. Free, under an hour.
Why it scored what it did: Claims 5, 6, 7, 8, 10, 11. If claims 5-6 hold, DME (durable medical equipment) payment for the ulcer indication is closed (A9283 (a HCPCS code for a supply), non-covered). The only route is CPT (Current Procedural Terminology) 29445 (claim 7unverified), and whether a locked walker may be reported under it is an open question with no…the rest of this reasoning
source either way (claim 8unverified). NCCI same-site bundling with debridement narrows it further (claim 11unverified), and no supply code is known to fit (claim 10unverified). This is a code that might apply, not a pathway. If claim 8unverified fails, the score falls toward 0-1.
What would settle it: Read MCD article A52457 and the current PFS (physician fee schedule) entry for 29445 (free). claim 8unverified needs a written coding opinion: an AMA CPT Assistant inquiry or a MAC (Medicare administrative contractor) medical-director query that a human has to file, which takes weeks.
Why it scored what it did: Claims 15, 16, 17, 18, 19. Incidence and prevalence are Medicare FFS (fee-for-service) only and from 2006-2008. The 29445 volume floor was not retrieved, no kit price is asserted, and addressable share is unknown. Price is structurally capped by claim 7unverified:…the rest of this reasoning
the kit has to fit in the supply portion of a ~$100 procedure payment, so revenue per application is small even if volume is large. The score is only partially evidenced and could move either way.
What would settle it: CMS (Centers for Medicare & Medicaid Services) Physician/Supplier Procedure Summary volume for CPT 29445 and the PFS practice-expense RVU (relative value unit) breakdown for 29445 (both free). Addressable share needs a published DFU (diabetic foot ulcer)-phenotype epidemiology paper, which is a PubMed search.
Why it scored what it did: Claims 20, 21. No blocker is known. The design deliberately avoids the only named families (Össur "patient compliance system") by carrying no electronics. Their claims, status and expiry are unread, and the field for keyed, locking or…the rest of this reasoning
tamper-evident orthosis closures has not been searched at all. The 3 means unexamined, not clear.
What would settle it: USPTO (United States Patent and Trademark Office) claims and legal status for US 8,043,245 and 8,454,546 (free). A CPC A61F 5/01 landscape search on lockable and frangible-release closures is a few hours of analyst time; a real FTO opinion needs counsel.
Why it scored what it did: Claims 21, 25, 26. It is a mechanical closure on a commodity walker, with no electronics, data or proprietary clinical evidence (claim 25unverified). Once the product is seen, any incumbent walker maker could copy it, and patentability of the…the rest of this reasoning
keyed/frangible closure is unexamined. The consumable closure set gives recurring revenue but no barrier.
What would settle it: The same CPC landscape search, read for patentability (novelty of the keyed plus frangible-release combination). Analyst hours; a patentability opinion needs counsel.
Why it scored what it did: Claims 1, 2, 3, 23, 24, 25. The mechanism rests on precedent: poor adherence with removable walkers (1), an RCT (randomised controlled trial) favouring the bandage-wrapped walker (2), and guideline preference for non-removable knee-high devices (3). Risk that is…the rest of this reasoning
specific to a device the patient cannot remove (pressure injury, hidden infection, falls, tampering; claim 24unverified) is uncharacterized. No prototype or data exist (25), and misuse of the emergency release is only an assumption (23).
What would settle it: Full text of PMID (PubMed identifier) 15735186 and the IWGDF 2023 offloading guideline (free). After that, a bench test of closure hold and release force plus a small usability/tamper study, both of which need a prototype and a budget.
Why it scored what it did: Claims 8, 12, 25. On the build side this is cheap and fast: a Class I exempt, non-powered, mechanical kit on a commodity shell. Time to first dollar is gated by the coding question (claim 8unverified) rather than by FDA, so the calendar is…the rest of this reasoning
open-ended until a coding opinion lands.
What would settle it: The claim 8unverified coding opinion (see Reimbursement), plus a contract-manufacturer quote for the closure set. The quote is a human request of a few weeks.
Why it scored what it did: Claims 4, 9, 26. Knee-high walkers are sold by several large orthopedic firms, and TCC-EZ holds the kit-based TCC niche under the same code (claims 9, 7). No locked walker was found, but that is a web-search absence (claim 26unverified), and…the rest of this reasoning
incumbents are well placed to add a lock.
What would settle it: FDA Registration & Listing search under the limb-orthosis regulation for walker makers, plus the Integra TCC-EZ product and coding pages (free). Recent launches or recalls would need a GUDID (Global Unique Device Identification Database)/MAUDE pass.
Why it scored what it did: Claims 28, 29. It would be a low-capital, cash-generative spoke if reimbursement holds. No domain dossier covers DFU offloading (29) and no seed was used (28), so it opens a new domain rather than compounding an existing one.
What would settle it: Tier 3 portfolio review against knowledge-base/_index/status.md. This is internal, so no external source settles it.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-022 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
<one sentence, selected from the Scores table's "What would settle it" column>
Nothing is waiting on a decision. The next move above is work, not a choice.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
To finish it:
domains: — run /research**Cheapest next test:** is still the unfilled _template.md placeholder — name the test, or the criterion checks nothingNo human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-022 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-022 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. <not yet written — later-stage artifact>
What would have to be true.
Cheapest next test: <one sentence, selected from the Scores table's "What would settle it" column>
Where the evidence actually stands. <run python3 engine/scripts/wrap_status.py --candidate idea-022>
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 4 | Claims 12, 13, 14. Scored against the stated intended use (non-removable offloading, no healing claim). Both carried routes are believed Class I, and the one the Generator prefers (890.3475) is believed exempt, so review burden would be…the rest of this reasoningclose to nil. It is a 4 rather than a 5 because neither regulation, class, exemption nor product code has been read, and because it is not yet known whether exemption limits or FDA's reading of a closed-on-limb assembly could push it off the Class I route. claim 14unverified prices the counterfactual: adding a healing claim means De Novo with outcome data. | eCFR text of 21 CFR 890.3475, 888.5940 and the 890.9/888.9 exemption limits, plus an FDA Product Classification database lookup for a product code. Free, under an hour. |
| Reimbursement pathway | 2 | Claims 5, 6, 7, 8, 10, 11. If claims 5-6 hold, DME payment for the ulcer indication is closed (A9283, non-covered). The only route is CPT 29445 (claim 7unverified), and whether a locked walker may be reported under it is an open question with no…the rest of this reasoningsource either way (claim 8unverified). NCCI same-site bundling with debridement narrows it further (claim 11unverified), and no supply code is known to fit (claim 10unverified). This is a code that might apply, not a pathway. If claim 8unverified fails, the score falls toward 0-1. | Read MCD article A52457 and the current PFS entry for 29445 (free). claim 8unverified needs a written coding opinion: an AMA CPT Assistant inquiry or a MAC medical-director query that a human has to file, which takes weeks. |
| TAM | 2 | Claims 15, 16, 17, 18, 19. Incidence and prevalence are Medicare FFS only and from 2006-2008. The 29445 volume floor was not retrieved, no kit price is asserted, and addressable share is unknown. Price is structurally capped by claim 7unverified:…the rest of this reasoningthe kit has to fit in the supply portion of a ~$100 procedure payment, so revenue per application is small even if volume is large. The score is only partially evidenced and could move either way. | CMS Physician/Supplier Procedure Summary volume for CPT 29445 and the PFS practice-expense RVU breakdown for 29445 (both free). Addressable share needs a published DFU-phenotype epidemiology paper, which is a PubMed search. |
| FTO / IP | 3 | Claims 20, 21. No blocker is known. The design deliberately avoids the only named families (Össur "patient compliance system") by carrying no electronics. Their claims, status and expiry are unread, and the field for keyed, locking or…the rest of this reasoningtamper-evident orthosis closures has not been searched at all. The 3 means unexamined, not clear. | USPTO claims and legal status for US 8,043,245 and 8,454,546 (free). A CPC A61F 5/01 landscape search on lockable and frangible-release closures is a few hours of analyst time; a real FTO opinion needs counsel. |
| Moat / defensibility | 1 | Claims 21, 25, 26. It is a mechanical closure on a commodity walker, with no electronics, data or proprietary clinical evidence (claim 25unverified). Once the product is seen, any incumbent walker maker could copy it, and patentability of the…the rest of this reasoningkeyed/frangible closure is unexamined. The consumable closure set gives recurring revenue but no barrier. | The same CPC landscape search, read for patentability (novelty of the keyed plus frangible-release combination). Analyst hours; a patentability opinion needs counsel. |
| Mechanism & clinical risk | 3 | Claims 1, 2, 3, 23, 24, 25. The mechanism rests on precedent: poor adherence with removable walkers (1), an RCT favouring the bandage-wrapped walker (2), and guideline preference for non-removable knee-high devices (3). Risk that is…the rest of this reasoningspecific to a device the patient cannot remove (pressure injury, hidden infection, falls, tampering; claim 24unverified) is uncharacterized. No prototype or data exist (25), and misuse of the emergency release is only an assumption (23). | Full text of PMID 15735186 and the IWGDF 2023 offloading guideline (free). After that, a bench test of closure hold and release force plus a small usability/tamper study, both of which need a prototype and a budget. |
| Capital intensity & time-to-revenue | 3 | Claims 8, 12, 25. On the build side this is cheap and fast: a Class I exempt, non-powered, mechanical kit on a commodity shell. Time to first dollar is gated by the coding question (claim 8unverified) rather than by FDA, so the calendar is…the rest of this reasoningopen-ended until a coding opinion lands. | The claim 8unverified coding opinion (see Reimbursement), plus a contract-manufacturer quote for the closure set. The quote is a human request of a few weeks. |
| Competitive intensity | 2 | Claims 4, 9, 26. Knee-high walkers are sold by several large orthopedic firms, and TCC-EZ holds the kit-based TCC niche under the same code (claims 9, 7). No locked walker was found, but that is a web-search absence (claim 26unverified), and…the rest of this reasoningincumbents are well placed to add a lock. | FDA Registration & Listing search under the limb-orthosis regulation for walker makers, plus the Integra TCC-EZ product and coding pages (free). Recent launches or recalls would need a GUDID/MAUDE pass. |
| Strategic fit & portfolio balance | 3 | Claims 28, 29. It would be a low-capital, cash-generative spoke if reimbursement holds. No domain dossier covers DFU offloading (29) and no seed was used (28), so it opens a new domain rather than compounding an existing one. | Tier 3 portfolio review against knowledge-base/_index/status.md. This is internal, so no external source settles it. |
To finish this packet:
domains: — run /research**Cheapest next test:** is still the unfilled _template.md placeholder — name the test, or the criterion checks nothingSource file: knowledge-base/candidates/idea-022.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md